NEW STRATEGIES IN THE TREATMENT OF MALIGNANT GLIOMAS: A BRIEF REVIEW OF SCIENTIFIC PUBLICATIONS OF THE ANNUAL MEETING OF SOCIETY THE NEURO-ONCOLOGY (SNO 2010) IN MONTREAL


如何引用文章

全文:

详细

The article presents most interesting reports on the treatment of malignant gliomas presented at Society of Neurooncology (SNO) symposium in 2010. Most of the papers on clinical neurooncology concerning the treatment of malignant gliomas were focused on current or completed studies using targeted drugs - bevacizumab, sunitinib, cediranib, silenzitid, nimotuzumab.

参考

  1. Neuro-Oncology, Volume 12, Supplement 4; ISSN 1522-8517 (Print); ISSN 1523-5866 (Online) Copyright © 2010. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://neuro-oncology.oxfordjournals.org/content/12/suppl_4.
  2. Kreisl TN, Smith P, Iwamoto F, et al. A phase II trial of sunitinib in the treatment of recurrent glioblastoma (GBM). Abs. OT-12, iv 71-72
  3. Batchelor T, Mulholland P, Neyns B, et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized study. Abs. OT-25, iv 75.
  4. Nabors B, Fink K, Mikkelsen T, et al. Cileengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: safety run-in results from a randomized controlled phase II study (CORE). Abs. OT-26, iv 75.
  5. Westphal M, Heese O, Warmuth-Metz M, et al. Current status of a phase III trail of nimotuzumab (anti-VEGF) in newly diagnosed glioblastoma. Abs. OT-13, iv 72.
  6. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: a randomized phase II trial of devacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Abs. NO-14, iv 39.
  7. Mоller S, Grunnet K, Hansen S. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Abs. OT-18, iv 73.
  8. Badruddoja MA, Pazzi MA, Stea B. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme. Abs. OT-07, iv 70.
  9. Sahebjam S, Garoufalis E, Guiot MC, et al. Bevacizumab for recurrent high-grade gliomas. NO-31, iv 43.
  10. Beverly DF, Linskey M, Bota D, et al. Retrospective study of bevacizumab and etoposide combination chemotherapy in patients with recurrent malignant gliomas who failed bevacizumab. NO-35, iv 44.
  11. Mrugala MM, Lee LK, Graham CA, et al. Bevacizumab and carboplatin for recurrent high-grade glioma. Abs. NO-81, iv 55.
  12. Desjardins A, Reardon DA, Peters KB, et al. Survival and toxicity update of the phase ii trial of bevacizumab (bv) in combination with temozolomide (tmz) and radiation therapy (rt) followed by bv, tmz, and irinotecan (cpt-11) for newly diagnosed glioblastoma multiforme (gbm) patients Abs. OT-34, iv 77.
  13. Gaziel TB, Soerensen M, Hasselbalch B. Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment. Abs. NO-17, iv 40.
  14. Puduvalli VK, Penas-Prado M, Gilbert MR, et al. Phase I study of vorinostat combined with isotretinoin and carboplatin in adults with recurrent malignant gliomas Abs. OT-02, iv 69.
  15. Friday BB, Buckner J, Anderson SK, et al. phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study Abs. OT-06, iv 70.
  16. Chamberlain MC, Graham C, Mrugala M, et al. Bendamustine for recurrent glioblastoma Abs. OT-11, iv 71.
  17. Goldlust SA, Singer S, DeAngelis LM, et al Metastatic glioblastoma (gbm): implications in the age of bevacizumab. Abs. AI-06, iv 2.
  18. Pollo B, Maderna E, Valletta L, et al. Prognostic significance of immunohistochemical markers identifying primary and secondary glioblastoma. Abs.PA-13, iv 80-81.
  19. Stupp R, Mason WP, et al. Radiotherapy plus concominent and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##